Login

Journal Image
Recent Patents on CNS Drug Discovery
ISSN (Print): 1574-8898
ISSN (Online): 2212-3954
VOLUME: 3
ISSUE: 1
DOI: 10.2174/157488908783421447









Neurokinin 3 (NK3) Receptor Modulators for the Treatment of Psychiatric Disorders

img
Author(s): Paul W. Smith and Lee A. Dawson
Pages 1-15 (15)
Abstract:
The neurokinin-3 (NK3) is one of the tachykinin peptide neurotransmitter / neuromodulator receptor family. NK3 receptors are predominantly expressed in neurons of both the peripheral and central nervous systems and in particular, in many of the forebrain areas, such as frontal, parietal and cingulate cortices, and basal ganglia structures implicated in psychiatric disease states. Consistent with this localization pattern, NK3 receptors appear to modulate monoaminergic and amino acid neurotransmission within these structures. Taken together these observations have lead to the speculation that modulators of NK3 receptor activity may have therapeutic utility in psychiatric diseases such as schizophrenia and affective disorders. This speculation has recently gained clinical credence through a number of reports of efficacy in placebo controlled studies. In this article, the authors review the recent patent literature highlighting the various NK3 receptor modulation strategies for potential therapeutic utility in psychiatric disease indications.
Keywords:
Tachykinins, neurokinin B, neurokinin 1, 2, 3 (NK1, NK2, NK3) receptors, schizophrenia, depression, panic, bipolar disorder, antagonist, modulator, agonist
Affiliation:
Psychiatry CEDD, Glaxo SmithKline, New Frontiers Science Park (North), Harlow, Essex, CM19 5AW,UK.